XML 32 R10.htm IDEA: XBRL DOCUMENT v3.21.2
Revenue Recognition
 9 Months Ended
Oct. 02, 2021
Revenue from Contract with Customer [Abstract]  
Revenue Recognition REVENUE RECOGNITION
Revenue is recognized when or as a customer obtains control of promised products. The amount of revenue recognized reflects the consideration we expect to be entitled to receive in exchange for these products.

Disaggregation of Revenue

We generated net sales in the following geographic locations(1) (in millions):
Three Months EndedNine Months Ended
October 2,
2021		September 26,
2020		October 2,
2021		September 26,
2020
U.S.$657.4 $638.7 $1,859.0 $1,913.4 
Europe(2)
334.5 326.6 1,037.6 1,011.0 
All other countries(3)
50.8 37.7 137.2 110.6 
Total net sales$1,042.7 $1,003.0 $3,033.8 $3,035.0 

(1) Derived from the location of the entity that sells to a third party.
(2) Includes Ireland net sales of $7.6 million and $17.4 million for the three and nine months ended October 2, 2021 respectively, and $10.8 million and $22.3 million for the three and nine months ended September 26, 2020, respectively.
(3) Includes net sales generated primarily in Mexico, Australia and Canada.
Product Category
        
The following is a summary of our net sales by category (in millions):
Three Months EndedNine Months Ended
October 2,
2021		September 26,
2020		October 2,
2021		September 26,
2020
CSCA(1)
Upper respiratory$121.9 $117.1 $345.8 $397.2 
Digestive health110.6 111.8 344.0 339.9 
Pain and sleep-aids108.4 102.6 292.9 325.7 
Nutrition105.3 100.3 293.3 291.5 
Oral self-care76.7 81.9 227.4 202.5 
Healthy lifestyle72.9 86.9 214.9 256.2 
Skincare and personal hygiene56.0 51.4 165.9 145.4 
Vitamins, minerals, and supplements8.1 6.3 24.3 19.1 
Other CSCA(2)
34.3 5.7 48.5 14.7 
Total CSCA694.2 664.0 1,957.0 1,992.2 
CSCI
Skincare and personal hygiene88.5 83.1 307.9 275.4 
Upper respiratory58.7 62.3 144.2 191.9 
Vitamins, minerals, and supplements54.7 52.9 162.8 139.9 
Pain and sleep-aids52.1 49.0 148.4 136.0 
Healthy lifestyle42.2 40.6 140.5 124.7 
Oral self-care24.4 25.2 72.4 68.8 
Digestive health10.1 6.8 28.3 17.9 
Other CSCI(3)
17.8 19.1 72.3 88.2 
Total CSCI348.5 339.0 1,076.8 1,042.8 
Total net sales$1,042.7 $1,003.0 $3,033.8 $3,035.0 

(1) Includes net sales from our OTC contract manufacturing business.
(2) Consists primarily of diagnostic and other miscellaneous or otherwise uncategorized product lines and markets, none of which is greater than 10% of the segment net sales.
(3) Consists primarily of our distribution business and other miscellaneous or otherwise uncategorized product lines and markets, none of which is greater than 10% of the segment net sales.

While the majority of revenue is recognized at a point in time, certain of our product revenue is recognized on an over time basis. Predominately, over time customer contracts exist in contract manufacturing arrangements, which occur in both the CSCA and CSCI segments. Contract manufacturing revenue was $80.8 million and $213.7 million for the three and nine months ended October 2, 2021, respectively and $76.3 million and $190.0 million for the three and nine months ended September 26, 2020, respectively.

We also recognize a portion of the store brand OTC product revenues in the CSCA segment on an over time basis; however, the timing difference between over time and point in time revenue recognition for store brand contracts is not significant due to the short time period between the customization of the product and shipment or delivery.

Contract Balances

The following table provides information about contract assets from contracts with customers (in millions):
Balance Sheet LocationOctober 2,
2021		December 31,
2020
Short-term contract assetsPrepaid expenses and other current assets$42.2 $19.7